SOTATERCEPT

Merck to Acquire Acceleron Pharma Inc.

Retrieved on: 
Thursday, September 30, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Sotatercept, REBLOZYL, Merck, Acceleron, SOTATERCEPT, REBLOZYL, MERCK, ACCELERON

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion.
  • Under the terms of the acquisition agreement, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Acceleron.
  • Centerview Partners LLC and J.P. Morgan Securities LLC were financial advisors to Acceleron and Ropes & Gray LLP its legal advisor.
  • This press release contains forward-looking statements about Acceleron Pharma Inc.s (Acceleron) financial results.

Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference

Retrieved on: 
Wednesday, May 19, 2021
Oncology, Health, FDA, Clinical trials, Pharmaceutical, Biotechnology, Hypertension, Organic compounds, Pulmonary hypertension, Chemical compounds, Chemistry, Riociguat, Iloprost, the SPECTRA Trial, Sotatercept, PAH, Acceleron, THE SPECTRA TRIAL, SOTATERCEPT, PAH, ACCELERON

Adverse events observed in the study were generally consistent with previously published data on sotatercept in PAH and in other diseases.

Key Points: 
  • Adverse events observed in the study were generally consistent with previously published data on sotatercept in PAH and in other diseases.
  • As of an interim data cut-off of February 25, 2021, treatment-emergent adverse events (TEAEs) were reported in 16 of 21 patients (76%).
  • Adverse events observed in the study were generally consistent with previously published data on sotatercept in other diseases.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.

Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference

Retrieved on: 
Wednesday, May 19, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Cardiology, Cardiovascular system, Circulatory system, Medicine, Angiology, Hypertension, Pulmonary hypertension, Vascular resistance, Cardiac catheterization, PVR, Pulmonary artery catheter, Blood vessel, Persistent fetal circulation, the PULSAR Trial, Sotatercept, PAH, Acceleron, THE PULSAR TRIAL, SOTATERCEPT, PAH, ACCELERON

We look forward to collecting additional, potentially confirmatory data through this ongoing open-label extension study and in the next phase of clinical development.\xe2\x80\x9d\nSotatercept was generally well tolerated in the trial.

Key Points: 
  • We look forward to collecting additional, potentially confirmatory data through this ongoing open-label extension study and in the next phase of clinical development.\xe2\x80\x9d\nSotatercept was generally well tolerated in the trial.
  • The primary endpoint of the trial was the change from baseline in pulmonary vascular resistance (PVR) over a 24-week treatment period.
  • PVR, as measured by right heart catheterization, is the resistance that the heart must overcome to pump blood through the pulmonary circulatory system.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.

Acceleron to Host Conference Call and Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) Presented at the American Thoracic Society (ATS) 2021 International Conference

Retrieved on: 
Tuesday, May 11, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Hypertension, Pulmonary hypertension, Health sciences, Health, PAH, Breakthrough therapy, Orphan drugs, Actelion, Sotatercept, PAH, Acceleron, SOTATERCEPT, PAH, ACCELERON

In preclinical studies, sotatercept was shown to reverse the vascular remodeling that is a hallmark of PAH.

Key Points: 
  • In preclinical studies, sotatercept was shown to reverse the vascular remodeling that is a hallmark of PAH.
  • Adverse events observed in the study were generally consistent with previously published data on sotatercept in other diseases.
  • Following the PULSAR results, sotatercept was granted Breakthrough Therapy designation from the FDA and Priority Medicines designation from the EMA in PAH.
  • In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial.